So much of what was said here is wrong and shows a poor...

So much of what was said here is wrong and shows a poor understanding of these trials.

Using the latest example with DME: All of the patient included in these trials had been receiving intensive anti-VEGF injections prior to bring randomised to receive either Eylea or Eylea+OPT.

The fact that these eyes (which had already been hammered with treatment before starting the trial, and who had chronic/well established disease) managed to gain letters at all is astonishing.

Don't forget, the first time these eyes received antiVEGF, prior to the study, they would have had a significant improvement in vision. Eventually the benefit plateaued out. Then, some of them received combo Eylea + OPT302, and they had greater improvement - beyond what they already had before starting the trial. These are patients who doctors may have thought had become as good as they were ever going to get - but this shows that there is still scope for improvement

This is a game changer for DME. It means you have other options for treatment besides intravitreal steroids when mainstream antiVEGF fails.